Marion E Meijer-van Gelder

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer

Reuben S Harris, Rachel Isaksson Vogel, John W M Martens, 2016, Science Advances.

Molecular profiling of platinum resistant ovarian cancer

Maurice P H M Jansen, E. Berns, P. Span, 2006, International journal of cancer.

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Maxime P Look, R. Vossen, J. Foekens, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study

Mieke Timmermans, J. Foekens, J. Klijn, 2005, Clinical Cancer Research.

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.

Mieke Timmermans, Maxime P Look, J. Foekens, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

Maurice P H M Jansen, Maxime P Look, J. Foekens, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.